There are currently four drug programs for cardiology patients, but access to them is severely limited due to administrative barriers, systemic shortcomings and uneven distribution of facilities offering such treatment, according to the report "Drug programs in cardiology: actual access vs. patient needs," prepared by the National Association of Patients with Heart and Vascular Diseases "EcoSerce."
The authors, a group of prominent cardiology experts and representatives of patient organizations, not only presented the current situation, but also proposed solutions to the problems blocking accessibility.
- "I hope that this document will be a contribution to a new opening, a discussion, including with policymakers, about what to do so that Polish patients or potential cardiac patients can benefit to a greater extent from the innovative therapies available in drug programs," Agnieszka Volchenko, president of the EcoHeart Association, said at Thursday's press conference.
Patients with cardiac conditions can currently be treated in four drug programs:
B.31 - pulmonary arterial hypertension
